Master's programme in Medical Biotechnology
The master’s programme in Medical Biotechnology aims to provide a detailed understanding of cutting-edge techniques used in molecular biology, with an emphasis on the analysis of biological samples and clinical applications. State-of-the-art techniques used to decipher biological systems, such as the genome or proteome, are covered, with an emphasis on high-throughput technological platforms and the analysis of biological information.
Medical Biotechnology at KTH
This two-year master’s programme comprises advanced courses regarding biotechnology tools used to analyse a variety of biological samples for life science research, as well as for health care applications within diagnostics and drug development. The student will be provided with in-depth knowledge about scientific methodologies used for comprehensive analyses of biological systems, and their applications for advanced health care or medical surveillance. The programme offers extensive biotechnology training to tackle global needs in the area of life sciences thus enabling students to prepare for careers in Sweden and internationally.
The program syllabus offers two tracks: medical applications of biotechnology and omics, each corresponding to half time studies. The student shall complete all courses within the chosen track. In addition, the student will tailor their education by combing their choice with a second track either of this programme, or any of the three tracks at the master’s programme in Industrial and Environmental Biotechnology. It is also possible to cherry pick courses from any track to create one’s own unique professional profile.
The tracks are designed to provide a holistic perspective on the use of biotechnology. Courses comprise both theoretical knowledge and practical application of theory from experimental design to bioinformatic and statistical analysis of raw data and interpretation of results. The curriculum provides a cross-platform approach to enable students to acquire a unique and individualised expertise that appeal to a wide span of employers. Students train problem-solving skills, project management as well as professional communication. The programme curriculum is designed, taught and continuously updated by a team of internationally recognised researchers within the different subject areas.
This is a two year programme (120 ECTS credits) given in English. Graduates are awarded the degree of Master of Science. The programme is given mainly at KTH Campus in Stockholm by the School of Engineering Sciences in Chemistry, Biotechnology and Health (at KTH).
The master's degree project is completed during the last term of the programme, where the student works on a research topic related to the courses included in the curriculum. The project may be carried out either in a research setting at KTH, in industry in Sweden or abroad, or in another university or research institute anywhere in the world.
The combination of technology, biology and chemistry taught in the Medical Biotechnology programme provides an attractive profile for a professional career in the biotechnological and pharmaceutical industry, or for further academic studies. These areas are expanding worldwide, which gives a graduate in Medical Biotechnology opportunities for a career in companies involved in the manufacturing of drugs, medical analyses and diagnostics, or further work in academic preclinical research, patent agencies, or as consultant.
Find out what students from the programme think about their time at KTH.
Faculty and Research
The School of Engineering Sciences in Chemistry, Biotechnology and Health conducts research in both fundamental and applied sciences with an emphasis on the medical aspects of human biology and the development of technical applications for medical care. The research activities conducted are multidisciplinary in nature, bringing together technology, medicine and bioinformatics. Active researchers are internationally well recognised, and conduct collaborative projects with leading international scientists as well as companies within the biotechnology private sector.[